Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Comcast Corporation (NASDAQ:CMCSA) shares fell 6.1% after reporting worse-than-expected Q2 sales results. Other notable stock movements include Azitra, Inc. (NYSE:AZTR) jumping 529% due to a new patent, and Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) rising 148% after advancing a study. General Motors Company (NYSE:GM) fell 6.1% after delaying EV projects.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 5:21 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 100 points. GE Aerospace reported better-than-expected Q2 earnings and raised its FY24 outlook. Azitra, Adial Pharmaceuticals, and Frequency Electronics saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Cellectar Biosciences experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 4:03 pm

US stocks edged higher with the Nasdaq Composite gaining 0.2%. General Motors reported better-than-expected Q2 earnings and raised its guidance. Azitra, Adial Pharmaceuticals, and Agape ATP saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Exicure experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 2:15 pm

Adial Pharmaceuticals shares are trading higher after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.